BioTechnical Institute of Maryland will close July 31 after revenue plunged from $1.27M to $537K, leaving local life‑sciences training in flux.

Dunwoody‑based Insight Global plans to hire more than 1,700 workers in 2026 to scale AI services and build an early‑career technical pipeline.

UGA researchers found pot marigold petals contain roughly 9% protein and functional traits that could make them useful as binders and emulsifiers in plant-based foods.

Novartis agreed to buy Myricx Bio for up to $1.5 billion, adding a novel ADC payload platform and underscoring the Boston‑area connections between small biotech and big pharma. The deal could reshape local hiring and partnership flows as programs move toward clinical development.

Ohio State researchers say a CRISPR vaccine beat leishmaniasis in animals as U.S. clinicians report rising cases. The team is preparing human trials.

More than 100 authors sued Anthropic in federal court, alleging the company used pirated books to train its Claude models and seeking statutory damages and a jury trial. The filing lists roughly 500 registered works and arrives amid other high‑profile AI copyright cases.

Crews have finished deactivation at ORNL’s Isotope Row and will begin demolition in July to clear a cluster of radioactive buildings for new research use.

Venice.ai raised $65M at a $1B valuation to scale a privacy-first AI platform, planning to buy GPUs and build data centers even as its Seattle co‑founder flags a new state tax.

SpaceX sent another batch of Starlink satellites from Cape Canaveral on July 5, and a second launch is slated for July 9 — keeping the Space Coast busy after 109 launches in 2025.

Cohen Orthopedic won a national surgical-robotics award as work on the Great Seal Medical Center is set to begin in July.

OHSU and collaborators mapped parasite peptides presented by HLA‑E that could let T‑cells provide cross‑species protection — a possible route to a universal malaria vaccine.

A 13‑year‑old Nashville boy became TriStar’s first commercial patient to receive an approved gene‑editing therapy that doctors say could end his sickle cell pain.

A University of Oregon‑commissioned study warns Oregon’s semiconductor cluster risks stagnation without faster action on land, power and the technician pipeline. The report links recent Intel cuts to the sector’s vulnerability.